Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?

• Published in: Journal of cancer research and therapeutics Vol. 20; no. 6; pp. 1726 - 1730
• Main Authors: Karabulut, Senem, Afsar, Cigdem U., Paksoy, Nail, Ferhatoglu, Ferhat, Dogan, Izzet, Tastekin, Didem
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer - Medknow 01.10.2024; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Edition: 2
• Subjects: Antigens; Cancer; Care and treatment; Caveolins; Chemotherapy; Diagnosis; Enzyme-linked immunosorbent assay; Health aspects; Medical prognosis; Methods; Original Article; Pancreatic cancer; Turkey; Caveolin-1; pancreatic cancer; diagnostic; serum
• ISSN: 0973-1482; 1998-4138; 1998-4138
• DOI: 10.4103/jcrt.jcrt_469_23

ABSTRACT Background: Caveolin-1 (CAV-1) is a vital component in cancer pathogenesis, as its expression determines the survival of patients with cancer. This study investigates CAV-1 serum levels in pancreatic adenocarcinoma (PA) patients and their role in tumor progression and prognostic factors. Method: The trial included 33 patients with pathologically confirmed pancreatic cancer (PC). The enzyme-linked immunosorbent assay (ELISA) method was used to measure the concentrations of CAV-1 in the blood. The study also included 20 healthy subjects. The statistical analysis was two-sided, and a P value of ≤ 0.05 was determined as statistically significant. Results: The median age of the subjects was 59 years (32-84 years) at the time of diagnosis. There were 13 (39%) female participants. In 21 (63%) patients, the primary focus was the pancreatic head. In 23 stage IV patients, hepatic metastasis (n = 19, 83%) was observed. Only one patient (3%) was still alive at the end of the study period. Palliative chemotherapy (CTx) was provided, with 39% of the 23 patients responding to it. The overall survival (OS) rate in this cohort was 41.3 ± 8.3 weeks at a 95% confidence interval (CI), after 25-58 weeks. Serum baseline CAV-1 values among patients with PA were significantly higher compared with controls (p = 0.009). Patients with poor performance status, a pancreatic head tumor, lower albumin levels, higher serum carcinoembryonic antigen (CEA) levels, and higher CA 19.9 levels had significantly higher serum CAV-1 levels (p = 0.01, P = 0.05, P = 0.03, P = 0.02, and P = 0.04, respectively). However, CAV-1 did not show any prognostic value (p = 0.75). Conclusion: Although serum CAV-1 is a useful diagnostic marker in PC patients, it is not a prognostic or predictive marker.